- Contineum Therapeutics, Inc. announced **positive topline data** from its **Phase 1b Positron Emission Tomography (PET) trial of PIPE-791** on **September 18, 2025**.  **[1855175_0001437749-25-029349_ex_860445.htm:0]** **[1855175_0001437749-25-029349_ctnm20250910_8k.htm:2]** 
- The trial confirmed that **PIPE-791 achieved high LPA1 brain receptor occupancy (RO)** in both **healthy volunteers and progressive multiple sclerosis (PrMS) patients**, demonstrating a clear pharmacokinetic correlation between drug exposure and receptor engagement.  **[1855175_0001437749-25-029349_ex_860445.htm:0]** **[1855175_0001437749-25-029349_ctnm20250910_8k.htm:2]** 
- **PIPE-791 showed a safety and tolerability profile consistent with previous clinical studies**, and the company anticipates its planned doses for future Phase 2 trials in idiopathic pulmonary fibrosis (IPF) and PrMS will **exceed 90% target coverage at trough with once daily dosing**.  **[1855175_0001437749-25-029349_ex_860445.htm:0]** **[1855175_0001437749-25-029349_ctnm20250910_8k.htm:2]**

Contineum Therapeutics (CTNM)